GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Insider Ownership

Curocell (XKRX:372320) Insider Ownership : 0.00 % (As of May. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Curocell's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Curocell's Institutional Ownership is 17.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Curocell's Float Percentage Of Total Shares Outstanding is 0.00%.


Curocell Insider Ownership Historical Data

The historical data trend for Curocell's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Insider Ownership Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Insider Ownership
Get a 7-Day Free Trial - - - - -

Curocell Quarterly Data
Dec19 Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Curocell Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Curocell Business Description

Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell Headlines

No Headlines